Drug Type Small molecule drug |
Synonyms S34-1040 |
Target |
Action inhibitors |
Mechanism 17β-HSD5 inhibitors(Aldo-keto-reductase family 1 member C3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Preclinical | China | 15 Jun 2026 |





